WO2006049273A1 - リガンドに特異的に結合するタンパク質を効率的に選別する手法 - Google Patents
リガンドに特異的に結合するタンパク質を効率的に選別する手法 Download PDFInfo
- Publication number
- WO2006049273A1 WO2006049273A1 PCT/JP2005/020346 JP2005020346W WO2006049273A1 WO 2006049273 A1 WO2006049273 A1 WO 2006049273A1 JP 2005020346 W JP2005020346 W JP 2005020346W WO 2006049273 A1 WO2006049273 A1 WO 2006049273A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- ligand
- target ligand
- library
- target
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Definitions
- the present invention relates to a method for selecting a protein that specifically binds to a specific ligand.
- Non-Patent Document 1 Gram et al., Proc. Natl. Acad. Sci., 89: 3576— 3580, 1 992
- Non-Patent Document 2 Cumbers et al., Nat. Biotechnol., 20: 1129— 1134, 2002 Disclosure of the Invention
- the present inventors conducted extensive research on a method for selecting a protein exhibiting specific binding to a target ligand from a diversified library, and as a result, identified a protein that specifically binds to the target ligand.
- the present invention has found a method that can be facilitated and made efficient.
- the present invention relates to a method for selecting a protein that specifically binds to a target ligand from a diversified library.
- the present inventors When screening proteins using the affinity for a ligand as an index, the present inventors non-specifically determine the target ligand non-specifically by measuring and comparing not only the target ligand but also the affinity for the control ligand at the same time. Thus, the present inventors have completed a method for easily and efficiently identifying a desired protein.
- the present invention relates to the following (1) to (11).
- the invention according to the first embodiment of the present invention is a method for selecting at least one protein that specifically binds to a target ligand from a diversified library
- step (b) contacting the target ligand with at least several proteins selected in step (a), incubating a mixture of the protein and the target ligand, and confirming the binding properties of the protein and the target ligand;
- step (c) contacting at least some proteins selected in step (a) with one or two specific control ligands, incubating a mixture of the protein and control ligand, and then reacting the protein and control ligand Determining whether or not are combined, and
- step (d) a step of selecting a protein that has been confirmed to bind to the target ligand in step (b) and has not bound to the control ligand in step (c);
- a method comprising:
- the invention according to the second embodiment of the present invention is as follows: “The protein to be contacted with the target ligand in the step (a) is presented on the surface of a host (1 ) ”.
- the invention according to the third embodiment of the present invention is as described in (1) or (2) above, wherein the target ligand and Z or control ligand are bound to a carrier. It's a method.
- the invention according to the fourth embodiment of the present invention is “the method according to (3) above, wherein the carrier is a magnetic bead”.
- the invention according to the fifth embodiment of the present invention is as follows: “Determination of the presence or absence of binding in the step (b) is performed by ELISA method, RIA method, surface plasmon resonance (SPR) method, blotting method, ligand bead The method described in (1) above and (4) above, which is carried out by a method selected from the group consisting of methods using a process.
- the invention according to the sixth embodiment of the present invention is “the method according to (5) above, wherein the target ligand and / or the control ligand are labeled”.
- the invention according to the eighth embodiment of the present invention is “the method according to (7) above, wherein the protein expression library is an antibody expression library”.
- the invention according to the ninth embodiment of the present invention is characterized in that the“ antibody expression library is a library constituted by cells presenting antibodies on the cell surface ” 8) The described method ”.
- the invention according to the tenth embodiment of the present invention is “the method according to (9) above, wherein the cell is a DT40 cell”
- the invention according to the eleventh embodiment of the present invention is “a protein selected by the method according to any one of (1) to (10) above”.
- the invention's effect [0007] By using the method according to the present invention, a protein that specifically binds to a target ligand can be rapidly and efficiently selected from a diversified library.
- Fig. 1 shows the production of antibodies that specifically bind to streptavidin using streptavidin magnetic beads from a diversified library of chicken DT40 cells displaying various antibody molecules on the cell surface. The results of ELISA using the cell culture supernatant are shown. The 22nd clone (arrow) is SD-10.
- FIG. 2 shows the results of ELISA using an egg white lysozyme rather than ovalbumin as a target antigen when selecting anti-rabbit IgG antibodies.
- Fig. 3 shows the detailed examination of the specificity of the antibodies finally selected in Fig. 1 for various ligands (streptavidin, ovalbumin, WgG (human IgG), skim milk) by ELISA. Show.
- the “diversified library” in the present invention means a library that can display a wide variety of proteins.
- the method according to the present invention can be applied to any library that can present a wide variety of proteins.
- a phage library capable of expressing various proteins and a library of cells capable of displaying various proteins on the cell surface are available.
- a library of cells capable of presenting antibody molecules is suitable.
- the “cell library” a library composed of chicken-derived DT40 cells capable of presenting various antibody molecules on the cell surface can be used (WO2004 / 011644).
- the “protein” in the present invention includes, in addition to naturally-occurring proteins, two or more amino acids such as mutants thereof, polypeptides constituting a part thereof, and artificially synthesized peptides. , A peptide bond) and the like.
- the “protein expression library” in the present invention is the above-mentioned “diversification library”. It is a concept that represents a host population that is included and can express a wide variety of proteins.
- the “host” includes a force S that can be assumed by those skilled in the art based on common general technical knowledge, such as prokaryotic cells, eukaryotic cells, phages or viruses.
- the protein expressed by the “host” may be expressed on the cell surface or in the cell of the “host”, or the protein may be cultured by culturing the “host”. May be expressed in a medium suitable for expressing.
- a “protein expression library” that can be applied to the method according to the present invention can be purchased commercially.
- the "antibody expression library” in the present invention is included in the above-mentioned "protein expression library” and is a concept representing a host population capable of expressing a wide variety of antibody molecules.
- the term “host” includes any force that can be assumed by those skilled in the art based on common general knowledge, such as prokaryotic cells, eukaryotic cells, phages or viruses, and preferably eukaryotic cells and phages. More preferred are animal cells and phages, and particularly preferred are DT40 cells and Ramos cells.
- target ligand and control ligand in the present invention are not particularly limited as long as they bind to a protein.
- proteins, nucleic acids, lipids, carbohydrates, low molecular compounds, etc. Include all that can be envisioned by those skilled in the art.
- control ligand” in the present invention may be any as long as it binds to a protein, and is not limited.
- control ligand used in the present invention may be one type or a plurality of types, but is not limited. For example, it may be two types or less, preferably one type. It is possible to select egg white lysozyme or ovalbumin, etc., in relation to the “target ligand”, such as multiple types of proteins, lipids, and carbohydrates contained in luc.
- target ligand or “control ligand” may be labeled, and any method and substance may be used as long as the label is a method and a labeled compound usually used in the art. Although not limited, a fluorescent label etc. can be used conveniently. 3. Selection of proteins that bind to the target ligand
- a protein that binds to a target ligand can be selected based on ordinary knowledge in the art.
- the target ligand is bound to an appropriate carrier, the bound target ligand is brought into contact with the protein present in the diversified library, incubated under appropriate conditions, and the resulting carrier-target ligand-protein complex. Can be recovered by centrifugation or the like, and a protein that binds to the target ligand can be selected.
- a protein that binds to the target ligand is obtained, if the host that expresses the protein is not a single clone, a single clone can be obtained by the limiting dilution method and subculture. Some of the proteins thus obtained bind with a different affinity to the target ligand.
- carrier used herein is not limited, and suitable ones such as sepharose beads, agarose beads, glass substrates, magnetic beads, etc. can be used, but magnetic beads are particularly preferred.
- Conditions for allowing the target ligand to bind to the protein can be set by those skilled in the art depending on the target ligand. Although there is no particular limitation, for example, when the protein to be selected is an antibody molecule, conditions for incubation at about 4 ° C to 37 ° C for about 15 minutes to 24 hours are set. can do.
- the protein force obtained as binding to the target ligand can be confirmed by a method well known in the art, for example, ELISA, RIA, surface, and the like.
- a plasmon resonance (SPR) method, a blotting method, a method using ligand beads, and the like can be used.
- the target ligand used here may be a labeled one.
- a substance that specifically binds to a protein that specifically binds to the target ligand for example, a protein such as an antibody, a nucleic acid, a lipid, etc.
- the binding specificity between the target ligand and the protein can be confirmed by an ordinary method using the non-substance.
- control ligand used here may be labeled.
- a substance that specifically binds to a protein that specifically binds to the control ligand for example, a protein such as an antibody, a nucleic acid, a lipid, etc.
- the binding specificity between the control ligand and the protein can be confirmed by a conventional method using the non-existing substance.
- a protein binds to the target ligand but does not bind to the control ligand depends on the method used.For example, the strength of the binding is expressed by the OD value (binding between the protein and the ligand). (Absorbance measured at a wavelength suitable for detecting), etc., indicating the binding with the target ligand. ⁇ D. Value / OD value indicating the binding with the control ligand is at least 2 or more, when ovalbumin is used as a control ligand, at least 1.0 or more, and when egg white lysozyme is used as a control ligand, when it is at least 0.7 or more, it specifically binds to the target ligand and Can be determined to be a protein having no binding property.
- the protein obtained through the above steps can be determined to be a protein that specifically binds to the target ligand.
- an antibody that specifically binds to streptavidin from a population of DT40 cells that induces somatic cell recombination at an immunoglobulin locus and produces various immunoglobulin molecules A method for selecting molecules will be described. See WO2004 / 011644 for the method of preparing the DT40 cell population.
- MDM medium (Invitrogen) was used with the addition of 10% FBS, 1% chicken serum, 100 units of penicillin, 100 ⁇ g / ml of streptomycin, and 55 ⁇ of 2-mercaptoethanol.
- Trichostatin ⁇ (Wako Pure Chemical Industries, Ltd.) was dissolved in methanol at 5 mg / ml as a stock and diluted with a suitable medium so that the final concentration was 2.5 ng / ml. Culturing was continued while maintaining the cell concentration at 10 5 to 10 6 cells / ml.
- Dynabeads M-280 Tosylactivated (Dynal) was used as the magnetic bead, and Dynal MPC (Dynal) was used as the magnetic stand. Wash 200 ⁇ 1 of beads 3 times with 500 ⁇ 1 of buffer ⁇ (0.1 M sodium diphosphate, pH 7.4), and then use 240 xg streptavidin (Nacalai Tester) in 400 ⁇ of Nouffer ⁇ . For 24 hours at 37 ° C with stirring by rotation. The beads were then washed twice with 500 xl of buffer C (10 mM sodium phosphate, pH 7.4, 150 mM NaCl, 0.1% BSA). Thereafter Buffer D (0. 2M Tri s-HCl , pH8. 5, 0.
- Dynabeads M-280 Tosylactivated (Dynal) was used as the magnetic bead, and Dynal MPC (Dynal) was used as the magnetic stand. Wash 200 ⁇ l of beads 3 times with 500 ⁇ l of buffer A (0.1 M sodium phosphate, pH 7.4), and then add 150 g of Usagi IgG (SIGMA) with Knoffer A at 200 mm. The reaction was carried out at 37 ° C with stirring by rotation. The beads were then washed twice with 200 C l of buffer C (10 mM sodium phosphate, pH 7.4, 150 mM NaCl, 0.1% BSA).
- buffer A 0.1 M sodium phosphate, pH 7.4
- SIGMA Usagi IgG
- Nother D (0.2M Tris-HCl, pH 8.5, 0.1% BSA) (200 zl) was added, and the mixture was allowed to react at 37 ° C for 4 hours with rotation while stirring, followed by blocking. Thereafter, the plate was washed twice with 500 ⁇ of buffer C and then suspended in 200 ⁇ l of buffer C containing 0.02% sodium azide.
- the cells bound to the magnetic beads were suspended in 500 ⁇ , added to 30 ml of medium, dispensed into a 96-well plate at 300 ⁇ , and cultured at 39.5 ° C.
- ELISA was performed on the culture supernatant.
- Table 1 shows the ELISA results for antibodies that react with streptavidin (28 clones in total) as 0 ⁇ D. Values, and the ELISA results for reactivity with ovalbumin from the same clones are also shown as 0 ⁇ D. Values. Show. Figure 1 is a graphic representation of Table 1.
- the culture supernatant used for analyzing the further specificity by ELISA was a medium prepared as follows in order to remove serum-derived IgM and the like. Immunoglobulin was removed as a precipitate from chicken serum (Invitrogen) with 50% saturated ammonium sulfate, and the supernatant was dialyzed against PBS. The volume increase caused by dialysis was corrected by concentration with Centri Prep (Amicon) to obtain antibody-removed chicken serum. This was prepared in AIM-V serum-free medium (Invitrogen) at a concentration of 6%. Cells were collected here at a concentration of about 10 6 / ml, cultured for 2 days, and the culture supernatant was removed and ELI SA was performed.
- the plate was washed 5 times with 200 ⁇ l of ELISA wash buffer, and horseradish peroxidase-conjugated goat anti-negri IgM antibody was diluted 2,000 times with PBS and added in 100 ⁇ l aliquots. After reacting at room temperature for 45 minutes, the plate was washed 5 times with an ELISA wash buffer, and then TMB + was added at 100 / il and reacted at room temperature for 4 minutes. Quantification was performed by measuring absorbance at 450 nm with an mQuant Biomolecular Spectrometer.
- Figure 2 shows the results of ELISA for specificity verification. It was confirmed that SD-10-1 obtained by ultradiluting SD-10 shown in Fig. 1 reacts strongly only with the initial target streptavidin. When the present invention is not applied, it is necessary to carry out the same process for 28 clones, so it has been found that there is a cost reduction effect of at least 28 times.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/666,562 US20080176753A1 (en) | 2004-11-08 | 2005-11-07 | Method of Efficiently Screening Protein Capable of Specific Binding to Ligand |
EP05805401A EP1811039A4 (en) | 2004-11-08 | 2005-11-07 | METHOD OF EFFICIENTLY SCREENING A PROTEIN CAPABLE OF BINDING SPECIFICALLY TO A LIGAND |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-324217 | 2004-11-08 | ||
JP2004324217 | 2004-11-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006049273A1 true WO2006049273A1 (ja) | 2006-05-11 |
Family
ID=36319271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/020346 WO2006049273A1 (ja) | 2004-11-08 | 2005-11-07 | リガンドに特異的に結合するタンパク質を効率的に選別する手法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20080176753A1 (ja) |
EP (1) | EP1811039A4 (ja) |
CN (1) | CN101052728A (ja) |
WO (1) | WO2006049273A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8808646B2 (en) | 2008-03-04 | 2014-08-19 | The Boeing Company | Wireless transmission of process data from within pressure vessels |
CN104829686A (zh) * | 2015-05-04 | 2015-08-12 | 上海交通大学 | 一种通过小分子化合物免疫共沉淀分离目标蛋白的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004011644A1 (ja) * | 2002-07-30 | 2004-02-05 | Riken | 体細胞相同組換えの促進方法及び特異的抗体の作製方法 |
JP2004503201A (ja) * | 1997-08-04 | 2004-02-05 | アプライド モレキュラー エボリューション,インコーポレイテッド | リガンド特異的結合分子の同定方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040142379A1 (en) * | 2003-01-16 | 2004-07-22 | Carlsberg Research Laboratory | Affinity fishing for ligands and proteins receptors |
-
2005
- 2005-11-07 CN CNA2005800375548A patent/CN101052728A/zh active Pending
- 2005-11-07 US US11/666,562 patent/US20080176753A1/en not_active Abandoned
- 2005-11-07 WO PCT/JP2005/020346 patent/WO2006049273A1/ja active Application Filing
- 2005-11-07 EP EP05805401A patent/EP1811039A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004503201A (ja) * | 1997-08-04 | 2004-02-05 | アプライド モレキュラー エボリューション,インコーポレイテッド | リガンド特異的結合分子の同定方法 |
WO2004011644A1 (ja) * | 2002-07-30 | 2004-02-05 | Riken | 体細胞相同組換えの促進方法及び特異的抗体の作製方法 |
Non-Patent Citations (2)
Title |
---|
See also references of EP1811039A4 * |
TAKAHASHI Y ET AL: "The direct cloning of the immunoglobulin VH genes from primary cultured B cells specific for a short peptide.", J BIOTECHNOL., vol. 49, no. 1-2, 1996, pages 201 - 210, XP004037108 * |
Also Published As
Publication number | Publication date |
---|---|
CN101052728A (zh) | 2007-10-10 |
EP1811039A4 (en) | 2009-08-05 |
US20080176753A1 (en) | 2008-07-24 |
EP1811039A1 (en) | 2007-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6603390B2 (ja) | 新規ペプチド・ライブラリー及びその使用 | |
JP4729701B2 (ja) | 小さな分析物のための非競合的な免疫アッセイ法 | |
CZ20013399A3 (cs) | Způsob izolace proteinů a analýzy proteinů, zejména hmotnostní analýzou | |
JP2012519208A (ja) | ビタミンdを検出するためのアッセイおよびそのための抗体 | |
Hu et al. | Combination of phage and Gram-positive bacterial display of human antibody repertoires enables isolation of functional high affinity binders | |
CN112415188B (zh) | 一种磁细胞及其制备方法和应用 | |
WO2006049273A1 (ja) | リガンドに特異的に結合するタンパク質を効率的に選別する手法 | |
Wang et al. | Cloning of anti-Gal Fabs from combinatorial phage display libraries: structural analysis and comparison of Fab expression in pComb3H and pComb8 phage | |
JP4566911B2 (ja) | コバラミン分析方法 | |
US20190248922A1 (en) | Affinity ligands and methods relating thereto | |
Anni et al. | Selection of phage-display library peptides recognizing ethanol targets on proteins | |
JP4729043B2 (ja) | 抗体ライブラリーをスクリーニングする方法 | |
Gonzalez-Techera et al. | High-throughput method for ranking the affinity of peptide ligands selected from phage display libraries | |
Ma et al. | Development in detection methods for the expression of surface-displayed proteins | |
Kiguchi et al. | Retrieving dissociation-resistant antibody mutants: an efficient strategy for developing immunoassays with improved sensitivities | |
JP2006149383A (ja) | リガンドに特異的に結合するタンパク質を効率的に選別する手法 | |
CA2483408A1 (en) | Sandwich assay and kit | |
EP2791677B1 (en) | General strategy for antibody library screening | |
KR101848977B1 (ko) | 타킷 바이오마커에 고특이적이며 고선택적 결합이 가능한 펩타이드 프로브 및 그를 이용한 비브리오 콜레라톡신 검출용 바이오칩 | |
CN114317546B (zh) | 一种用于检测evd68病毒的核酸适配体、试剂盒及应用 | |
CN116023495B (zh) | 一种抗cd40纳米抗体及其制备方法与应用 | |
Ball Jr et al. | Selection of peptidic mimics of digoxin from phage-displayed peptide libraries by anti-digoxin antibodies | |
Chen et al. | Isolation of human antibodies against hepatitis E virus from phage display library by immobilized metal affinity chromatography | |
CN117417450A (zh) | 髓过氧化物酶结合蛋白、制备方法和应用 | |
CN117209600A (zh) | Ss-b结合蛋白、制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200580037554.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005805401 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005805401 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11666562 Country of ref document: US |